GARP-expressing Tregs as a source of immunosuppressive TGF-β1 in human tumors.

(en) Most cells produce latent transforming growth factor-beta 1 (TGF-β1), but only very few activate the cytokine via cell type-specific mechanisms. TGF-β1 favors cancer progression by suppressing anti-tumor T cell responses. Which cells produce this immunosuppressive TGF-β1 in human tumors is unknown. Putative sources include cells expressing the glycoprotein A repetitions predominant (GARP) protein, comprising mostly activated regulatory T cells (Tregs) (GARPFOXP3 cells) and blood endothelial cells (BECs). We performed multiplexed immunohistofluorescence and computerized image analyses on 186 tumor samples from 5 cancer types (colorectal, urothelial, lung and breast primary carcinomas and melanoma metastases), compared to patient-matched adjacent non-cancerous tissues. GARP Tregs were present in 29-75% of the various types of tumor samples. Their proportion was higher in tumors than non-cancerous tissues but unexpectedly it did not correlate with that of tumor-infiltrating T lymphocytes (TILs). The density of blood vessels was similar across samples, with more than half expressing GARP. The proportion of cells undergoing TGF-β1 signaling, which express the phosphorylated form of mothers against decapentaplegic homolog 2 (pSMAD2), was approximately twice as high in tumors compared to non-cancerous tissues. In most tumor types, pSMAD2 TILs were twice closer to the nearest FOXP3 cell than after random repositioning, at a distance (~ 70 µm) consistent with short-range paracrine TGF-β1 signaling. In contrast, pSMAD2 non-T cells and pSMAD2 TILs were not closer to FOXP3 cells, neither were pSMAD2 cells (TILs and others) to BECs. We conclude that, in human tumors, GARP-expressing Tregs rather than BECs appear to represent a source of TGF-β1 suppressing nearby TILs. This local immunosuppression could be blocked with anti-GARP:TGF-β1 antibodies, particularly to treat patients with tumors heavily infiltrated by GARP-expressing Tregs.

Affiliations

Citations

APA
Chicago
FWB

Van Meerbeeck, P., Maatougui, D., de Streel, G., Vaherto, N., Marbaix, E., Aboubakar Nana, F., Van den Eynde, M., Devaux, A., Carrasco, J., Noel, A., van Baren, N., & Lucas, S. (2025). GARP-expressing Tregs as a source of immunosuppressive TGF-β1 in human tumors. Cancer immunology, immunotherapy : CII, 74(10), 308 [1-11]. https://doi.org/10.1007/s00262-025-04157-2 (Original work published 2025)